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Background: Induction of potent long lasting effector T cell responses against liver stage malaria antigens strongly
correlates with protection from malaria. While Adenovirus serotype 5 (Ad5) based malaria vaccine platforms have
the ability to induce potent effector T cell responses against transgenes, high rates of pre-existing Ad5 immunity in
malaria endemic regions has prompted study of alternative Ad serotype based malaria vaccines as replacements for
Ad5 based malaria vaccines. The research described in this article examines the utility of alternative serotype
adenovirus serotype 4 (Ad4) expressing a sporozoite surface protein (circumsporozoite protein (CSP)) (Ad4-CSP) to
induce immune responses against CSP. The immunogenicity of Ad4-CSP was also tested in homologous and
heterologous prime boost vaccinations in both Ad5 naïve and Ad5 immune backgrounds as compared to use of
Ad5-CSP.
Results: In Ad5 naïve animals, use of Ad4-CSP priming vaccinations followed by boosting with Ad5-CSP (Ad4-CSP/
Ad5-CSP) maximally increased the numbers of CSP specific cytokine secreting cytotoxic T cells relative to repeated
use of Ad5-CSP. The Ad4-CSP/Ad5-CSP regimen also induced equivalent levels of CSP specific cell killing as did
homologous prime-boost vaccinations with Ad5-CSP, despite stimulating lower numbers of CSP specific cytotoxic
T cells. Priming with Ad4-CSP followed by a homologous boost resulted in significantly less CSP specific humoral
responses than any other vaccination regimen tested in Ad naïve animals. In Ad5 immune animals, addition of
Ad4-CSP in homologous or heterologous prime boost resulted in inductions of higher CSP specific responses than
animals repeatedly vaccinated with Ad5-CSP alone. However, the observed responses were well below those
observed in similarly treated Ad naïve mice.
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Conclusions: While the Ad4-CSP/Ad5-CSP and Ad5-CSP/Ad5-CSP vaccination regimens resulted in equivalent CSP
specific killing in Ad naïve animals, Ad4-CSP/Ad5-CSP achieved this result with a lower percentage of CSP specific
CD8+ T cells and a higher number of IFNγ secreting cells, suggesting that the Ad4-CSP/Ad5-CSP vaccination
regimen elicits more efficient cytotoxic T cells. In Ad5 immune animals use of Ad4-CSP improved CSP specific
immune responses as compared to repeated use of Ad5-CSP, but could not achieve the levels of immunogenicity
observed when the same vaccine regimens were used in Ad naïve animals. These data indicate the existence of
some level of immunological cross-reactivity between these two adenovirus subgroups. Based on these results, it is
suggested that future studies should undertake similarly stringent analyses of alternative Ad serotypes to establish
their effectiveness as replacements for Ad5.
Keywords: Serotype 5, Serotype 4, Adenovirus, Malaria, Circumsporozoite protein, Vaccine, Heterologous,
Homologous, Prime, BoostBackground
Despite use of prophylactic medications and vector con-
trol, malaria continues to be one of the world’s most
deadly health concerns claiming the lives of almost
1 million people annually. The protozoan parasite,
Plasmodium falciparum, accounts for about 90% of
these deaths [1]. Numerous P. falciparum targeted vac-
cine studies are currently underway in efforts to elimin-
ate this dangerous killer. The P. falciparum derived
circumsporozoite protein (CSP) is the most studied and
commonly used antigen for the purpose of developing a
vaccine against malaria [2-6]. CSP is abundant on the
surface of the sporozoite, and is also present in the
plasma membrane and cytosol of plasmodium infected
hepatocytes. CSP is a 58 kD protein composed of a
C-terminus containing the thrombospondin-like type I
repeat region (TSR involved in liver sinusoid attach-
ment), a central region of [NANP] repeats, and a
N-terminal site that when in contact with the liver si-
nusoid is cleaved exposing the TSR [7-9].
Of the several malaria vaccine vectors that target CSP,
the most successful to date is a vaccine formulation that
consists of a novel fusion protein between the hepatitis
B surface protein (HBsAg) and CSP, and additional adju-
vants. This formulation, referred to as RTS,S/AS01B, is
currently in a phase 3 clinical trial [10]. This vaccine has
been able to confer protection to 56% of vaccinated indi-
viduals [3,10-15]. Although promising, the results also
suggest that more potent immune responses may be
required to achieve higher levels of protection. For this
reason other vectors and immunogenic strategies in-
corporating CSP are being pursued in efforts to develop
a highly efficacious, malaria specific vaccine.
Recombinant adenovirus serotype 5 (rAd5) based
vaccines are important in this regard as they have been
confirmed to elicit potent adaptive responses against
expressed transgenes [16-18]. Multiple studies haveutilized rAd5s genetically engineered to express CSP in
human and mouse models of malaria [6,19,20]. However,
pre-existing Ad5 immunity is common in regions
where malaria is endemic, and the presence of neutral-
izing antibodies against Ad5 has been shown to hinder
Ad5 based vaccine efficacy [21-23]. It has been
hypothesized that the use of alternative serotype based
rAds may induce improved immunogenic responses to
antigens irrespective of pre-existing Ad5 immunity, for
example in HIV vaccine development [24,25]. There
are at least 52 different human Adenovirus serotypes.
Adenovirus serotypes are divided into subgroups A-F
based primarily on anti-sera neutralization. Since Ad5 is
a member of subgroup C, it is hypothesized that alterna-
tive serotypes from other subgroups would not be neu-
tralized by Ad5 antibody and therefore, could still be
utilized to infect cells and stimulate immunity to an
expressed transgene. Use of alternative serotype based
Ad vectors can serve other important purposes aside
from stimulating immune responses in Ad5 immune
patients. Heterologous prime boost regimens where the
prime and boost vaccinations are derived from two dif-
ferent Ad serotypes based vaccines can provide greater
inductions of immunity than homologous prime boost-
ing with a single Ad serotype based vaccine [26-28].
In this context, Ad4 based vectors may be promising
for use in malaria specific applications. The efficacy and
safety of Ad4 vaccine platforms has been established.
For instance, as the principal serotype causing Acute
Respiratory Disease (ARD) in military recruits, an orally
administered, live Ad4 virus was utilized for decades in
vaccinations of recruits against ARD [29-32]. More re-
cently, Ad4 based vaccines have been successfully
utilized in HIV vaccine strategies in dog and chimpanzee
models [24,25]. This research article analyses the ability
of an Ad4-based malaria specific vaccine expressing CSP
to stimulate potent immune responses when used in
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an Ad5 vaccine also expressing CSP, both in the context
of Ad5 naïve and Ad5 immune animals.Methods
Vector construction
The open reading frame (ORF) of the P. falciparum CSP
gene, composed of a codon optimized consensus of sev-
eral P. falciparum CSP sequences, was incorporated into
an E1, E3 deleted adenovirus serotype 5 vector under the
control of a cytomegalovirus (CMV) enhancer/promoter
element as previously described [33]. The same CSP con-
sensus sequence was incorporated into an E1, E3 deleted
adenovirus serotype 4 vector under the expressional
control of the same CMV enhancer/promoter element.
Ad4 vector construction was performed as previously
described with an Ad4 recombination based production
system [34].Animal procedures
All animal procedures were approved by the Michigan
State University Institutional Animal Care and Use
Committee (IACUC). 6–8 weeks old male BALB/cJ mice
were injected intramuscularly (IM) into the tibialis an-
terior of the right hind limb. Total injected volume was
20 μl. Splenocytes and plasma were collected. All proce-
dures with rAds were performed under BSL-2, and all
vector treated animals were maintained in ABSL-2 con-
ditions. Care for mice was provided in accordance with
PHS and AAALAC standards.ELISA
ELISA-based antibody assays were completed as previ-
ously described [16]. High-binding flat bottom 96-well
plates were coated with 0.2 μg of purified CSP per well
in a volume of 100μL and incubated overnight at 4°C.
Plates were washed with PBS-Tween (0.05%) then trea-
ted with blocking buffer (3% bovine serum albumin) for
1 hour at room temperature. Plasma from ad naïve ani-
mals was diluted (1:100, 1:200, 1:400) in blocking buffer.
Plasma from Ad immune animals was analysed with-
out dilution. Samples were incubated for 1 hour at room
temperature. Wells were washed with PBS-Tween
(0.05%) and HRP antibody (Bio-Rad) was added at
1:4,000 dilution in PBS-Tween. Tetramethylbenzidine
(TMB) (Sigma-Aldich) was added to each well and the
reaction was stopped with 2 N sulfuric acid. Plates are
read at 450 nm in a microplate spectrophotometer. Sub-
isotyping titering was completed with a hybridoma sub-
isotyping kit (Calbiochem, La Jolla, CA) with plasma
dilutions of 1:100, 1:200 and 1:400. Statistical analyses
were performed using Student t-test.Isolation of lymphocytes
Splenocytes from individual mice were prepared by
physical disruption of the spleen. The spleen was passed
through a sterile 40 μm nylon mesh cell strainer (Fisher
Scientific, Pittsburgh, PA). Red blood cells were lysed
using ACK lysis buffer (Invitrogen, Carlsbad, CA) re-
maining cells were resuspended in RPMI 1640 supple-
mented with 10% FBS and penicillin/streptomycin/
fungizone [35].
ELISPOT analysis
ELISpots were performed in accordance to manufac-
turer’s protocol using the Ready-set Go IFNγ mouse
ELISpot kit produced by eBiosciences (San Diego, CA).
Splenocytes were stimulated ex vivo with 4 μg/mL of
the >98% pure CSP immunodominant peptide NYD-
NAGTNL (amino acids 43–51 of the CSP sequence)
(GenScript Piscataway, NJ) [36]. Spots were counted and
photographed by an automated ELISPOT reader sys-
tem (Cellular Technology, Cleveland, OH). Ready-set Go
IFNγ and IL-2 mouse ELISPOT kits purchased from
eBioscience (San Diego, CA).
Cell staining and flow cytometry
Splenocytes were stained with various combinations of
the following antibodies: APC-Cy7-CD3, Alexa Floure700-
CD8, PerCpCy5.5-CD127, PE-Cy7-CSP (NYD) tetramer,
V450-CD62L, PE-Cy7-TNFα, APC-IFNγ, and Granzyme
B- (4 μg/ml) (All obtained from BD Biosciences, San
Diego, CA). Cells were incubated on ice with the appro-
priate antibodies for 30 minutes, washed, and sorted
using an LSR II instrument and analysed using FlowJo
software. For intracellular cytokines staining, cells were
surface stained, fixed with 2% formaldehyde (Poly-
sciences, Warrington, PA), permeabilized with 0.2%
saponin (Sigma-Aldrich, St. Louis, MO), and stained for
intracellular cytokines. Large cells and debris were
excluded in the forward- and side-scatter plot, to
minimize background levels of staining caused by non-
specific binding of antibodies; cells were initially stained
with CD16/32 FcR III/II antibody. In addition the violet
fluorescent reactive dye (ViViD, Invitrogen) was used as
a viability marker to exclude dead cells from the ana-
lysis [37]. Blood was isolated by retro-orbital bleeds
and PBMCs were isolated using Lympholyte-Mammal
(Cedarlane, Burlington NC). Tetramer staining of PBMCs
was completed using a PE conjugated MHC-I (H2d)
tetramer folded with the NYDNAGTNL peptide
generated at the NIH Tetramer Core Facility.
In vivo CTL assay
BALB/cJ were injected with a priming dose of 1×1010
vp/mouse of either Ad5-CSP or Ad4-CSP followed by
a heterologous or homologous boosting injection of
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28 days post initial injection, syngeneic splenocytes were
isolated and pulsed with either an irrelevant peptide or
peptide specific to the P. falciparum circumsporozoite
antigen (NYDNAGTNL) for 1 hour at 37°C. Irrelevant
peptide pulsed cells were stained with 1 μM CFSE
(CFSELow) while CSP-peptides pulsed cells were stained
with 10 μM CFSE (CFSEHigh). Naïve and immunized
mice were injected with equivalent amount of both
CFSELow and CFSEHigh stained cells via the retro-orbital
sinus. After 18 hours splenocytes were harvested and
sorted on an LSRII flow cytometer. FlowJo software was
used to determine percentages of CFSE stained cells. %
Specific killing = 1-((% CFSEHigh / % CFSELow) immunized /
(% CFSEHigh / % CFSELow) non-immunized).
Statistical analysis
Statistically significant differences in ELISpot assays
were determined using either Two Way ANOVA with
a Bonferroni post-hoc test or a One Way ANOVA with a
Student-Newman-Keuls post-hoc test (p value < 0.05). For
ELISA analysis, a t-test was used to assess significance
between treatments. For multiparameter flow cytometry,
a One Way ANOVA with a Student-Newman-Keuls
post-hoc test was used. For in vivo CTL assay, a One Way
ANOVA with a Student-Newman-Keuls post-hoc test was
used. All graphs in this paper are presented as Mean±SD
with the exception of ELISA graphs, which use
Mean ± SE. GraphPad Prism software was utilized for
statistical analysis.
Results
rAds of serotype 4 and serotype 5 were engineered to
express a codon optimized form of CSP using methods
previously described [33,34]. Four vaccination regimens
were utilized; 1. Ad5-CSP/Ad5-CSP, 2. Ad5-CSP/Ad4-
CSP, 3. Ad4-CSP/Ad4-CSP, and 4. Ad4-CSP/Ad5-CSP,
where the Ad serotype used in the priming vaccination
is immediately followed by the serotype of the boosting
vaccination in each vaccine regimen or group. Initially,
(day 0) Ad naïve BALB/cJ mice were injected with either
Ad4-CSP or Ad5-CSP (1x1010 vp/mouse) (n = 10). 14 days
later 5 mice from each treatment group received a hom-
ologous boost (same Ad-CSP serotype vaccine) of 1x1010
vp/mouse, the other five mice from the same group
received a heterologous boosting vaccination of 1x1010
vp/mouse with the alternative Ad-CSP serotype vaccine.
28 days after the priming vaccinations, splenocytes were
harvested from the animals and stimulated with the CSP
derived peptide (NYDNAGTNL) and the number of
IFNγ secreting splenocytes were quantified by ELISpot.
While every vaccine treatment resulted in a significant
increase in the numbers of CSP responsive INFγ se-
creting splenocytes when compared to non-vaccinatedanimals, the Ad4-CSP/Ad5-CSP heterologous prime
boosting vaccine treatment group induced significantly
higher numbers of IFNγ secreting splenocytes than any
other treatment group (Figure 1A). Of note, previous
experiments have confirmed that simple administration
of Ad vaccines does not significantly increase numbers
of IFNγ secreted cells, for example when splenocytes
derived from Ad vaccine treated animals are stimulated
with control peptides [33-35]. These results were fur-
ther supported by intracellular staining with antibodies
against CD3, CD8, and IFNγ, as the percentage of CSP
responsive CD3+ CD8+ IFNγ+ cells present in spleno-
cytes derived from mice vaccinated with the Ad4-CSP/
Ad5-CSP regimen were significantly higher when com-
pared to splenocytes from animals treated with the other
vaccination strategies (Figure 1B). Intracellular staining
was also performed to enumerate the frequency of TNF
and Granzyme B producing CD8+ T cells present in the
spleens of the variously vaccinated animals. Again, the
Ad4-CSP/Ad5-CSP experimental vaccination regimen
appeared to confer the most robust immune responses
against CSP, as it was the only treatment to induce
significantly higher percentages of CSP responsive CD3+
CD8+ TNF+ cells as compared to non-vaccinated animals
(Figure 1C). Interestingly, none of the vaccination
strategies induced significantly higher percentages of
CSP responsive CD3+ CD8+ Granzyme B+ cells as
compared to non-vaccinated animals; however, ani-
mals from the Ad5-CSP/Ad4-CSP vaccination group
had significantly lower percentages of CD3+, CD8+,
Granzyme B+ T cells as compared to all other treat-
ment groups (Figure 1D).
As detected by use of the NYDNAGTNL tetramer, each
of the vaccination regimens induced significantly higher
percentages of CD3+ CD8+ T cells in the spleen as com-
pared with non-vaccinated control animals (p < 0.001)
(Figure 2A). Of the four groups, the Ad4-CSP/Ad5-CSP
heterologous prime boosting regimen induced the lowest
percentage of CD3+ CD8+ tet+ T cells, a decrease that was
statistically significant as compared to both the Ad5-CSP/
Ad5CSP and the Ad5-CSP/Ad4-CSP treatment groups
(p< 0.01; p< 0.05 respectively). When peripheral blood
mononuclear cells (PBMCs) from the vaccinated mice
were similarly analysed, again all groups of vaccinated
mice had significantly increased numbers of CD3+ CD8+
tet+ T cells present as compared to non-vaccinated mice.
However, the Ad4-CSP/Ad4-CSP treated animals elicited
the lowest percentages of CD3+ CD8+ tet+ T cells of the
four groups, this decrease reaching statistical significance
when this group was compared to both the Ad5-CSP/
Ad5-CSP and Ad5-CSP/Ad4-CSP treatment groups
(p< 0.05 for each group) (Figure 2B).
Ad vectors are known to elicit strong Tem cell re-













































































































































Figure 1 Ad4-CSP/Ad5-CSP heterologous prime boost results in improved quality of T cell response. A prime injection of 1 × 1010 vp/
mouse Ad4-CSP followed by a boost of 1 × 1010 vp/mouse of Ad5-CSP resulted in significantly more IFNγ secretion by splenocytes measured by
ELISpot (A) and CD3+ CD8+ T cells measured by flow cytometry (B). Ad4-CSP/Ad5-CSP was the only treatment to stimulate a significantly higher
percentage of TNFα production as compared to unvaccinated animals (C). Cells were stained with CD3-APC-Cy7, CD8-Alexa flour700,
TNFα-PE-Cy7, IFNγ-FITC, and Granzyme B-APC. Bars represent ± standard error. Statistical analysis was completed using One Way ANOVA with
Student-Newman-Keuls post-hoc test, *, **, *** denotes significance over naïve, P< 0.05, P< 0.01, P< 0.001.
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vaccine as Tem cell responses have been shown to be
beneficial in protecting against liver stage malaria [38].
The magnitude of CSP-specific central memory and ef-
fector memory CD8+ T cell responses was compared in
each of the various prime boost regimens induced in
splenocytes and PBMCs harvested 14 days after the
boosting vaccinations. All prime boost regimens demon-
strated much higher percentages of CSP specific Tcm
cells and Tem cells than was observed in non-vaccinated
animals as indicated by the percent of CD127+ CD62L+
and CD127+ CD62L- tet+ T cells present in the spleno-
cytes (Figure 3B-C). The percentage of CSP specific Tcm
and Tem cells circulating in the blood was also analysed
and it was found that the Ad5-CSP/Ad4-CSP vaccinationgroup was the only group that had a significantly higher
percentage of CSP specific Tcm cells in circulating blood
when compared to non-vaccinated animals, while all vac-
cinated animals had higher percentages of CSP specific
Tem cells present in this compartment as compared to
non-vaccinated animals (Figure 3D-E). When memory
phenotypes were analysed by gating on tetramer positive
cells first, followed by gating for CD127 and CD62L, the
tetramer positive cells of all groups had similar memory
phenotypes as defined by comparison of the percentages
of tet+ cells that were Tem and those that were Tcm cell.
Splenocytes from all treatments were analyzed for the
presence of anti-Ad4 and/or anti-Ad5 antigen specific
IFNγ secreting T cells by ELISpot. There was no sig-








































































Figure 2 Ad5-CSP/Ad5-CSP vaccination resulted in higher percentage of tetramer positive CD8+ T cells than Ad4-CSP/Ad5-CSP in the
spleen. Splenocytes and PBMCs were collected two weeks after final vaccination. All vaccination regimens resulted in significantly higher
percentage of CD3+ CD8+ NYDNAGTNL tetramer positive T cells in the spleen (A) and circulating blood (B) as measured by flow cytometry, cells
were stained with CD8-Alexa flour700, CD3-APC-Cy7, and CSP (NYD)-Tetramer-PE. Ad5-CSP/Ad5-CSP stimulated a higher percentage of CD3+ CD8
+ tet+ than Ad4-CSP/Ad5-CSP treated animals in the spleen (A) and higher percentage of CD3+ CD8+ tet+ than Ad4-CSP/Ad4-CSP in the
circulating blood (B). Bars represent ± standard error. Statistical analysis was completed using One Way ANOVA with Student-Newman-Keuls post-
hoc test, *, **, *** denotes significance over naïve, P< 0.05, P < 0.01, P< 0.001.
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CSP/Ad4-CSP treatment had significantly less Ad5
specific IFNγ secreting cells than all other vaccination
regimens, and were not significantly different than naïve
animals. Likewise, animals that were vaccinated with
Ad5-CSP/Ad5-CSP had significantly less Ad4 specific
IFNγ secreting cells than animals that received Ad4-CSP
injections and were also not significantly different than
naïve animals (Additional file 1).
The effect of prime boost vaccinations combining
Ad4-CSP and Ad5-CSP on CSP specific antibody pro-
duction, as compared to homologous prime boosts using
the same vectors was then determined. Plasma was col-
lected from BALB/cJ mice injected with the four prime
boost regimens 28 days post initial injection and was
tested by ELISA for total anti-CSP IgG antibody levels.
Mice from the Ad4-CSP/Ad4-CSP vaccination group
demonstrated significantly higher plasma levels of IgG
anti-CSP relative to unvaccinated animals at the 1:100
dilutions (p < 0.05) (Figure 4). All other vaccination regi-
mens induced significantly higher levels of anti-CSP IgG
as compared to both the non-vaccinated animals and
animals receiving the Ad4-CSP/Ad4-CSP regimen
(p < 0.001) (Figure 4). Similar trends were observed
when sub-isotyping analysis was performed for anti-CSP
IgG1, IgG2a, IgG2b, and IgG3 levels (Additional file 2).
IgG2a/IgG1 ratio was analysed as an indirect assessment
of Th1 vs. Th2 immune responses in animals treated
with the vaccine regimens; however the Th1/Th2 ratio
was not significantly different with use of any of the vac-
cination regimens (Additional file 3).To assess the efficacy of Ad4 based vaccination regi-
mens to induce functional, CSP specific cytolytic T cell
responses, CSP specific cytotoxic T lymphocyte killing
in vivo was measured. BALB/cJ mice were vaccinated
with the homologous and heterologous prime boost
regimes as described above. 28 days after the initial vac-
cination, splenocytes from naïve mice were collected and
incubated with either a high concentration of CFSE
(10 μM) and NYDNAGTNL peptide or a low concentra-
tion of CFSE (1 μM) and a non-specific peptide. Stained
and peptide pulsed splenocytes were then mixed at equal
quantities and injected intravenously into vaccinated or
non-vaccinated animals. After 18 hours, CSP specific cell
killing was measured in the spleens of the vaccinated
animals by flow cytometry. Only animals that received
the Ad5-CSP/Ad5-CSP and Ad4-CSP/Ad5-CSP vaccin-
ation regimens achieved significantly elevated levels of
CSP specific cell killing as compared to non-vaccinated
animals (p < 0.01) (Figure 5).
Given the high seroprevalence of wild type Ad5 in
adults living in malaria endemic regions, the ability of
these homologous and heterologous prime boost vaccine
regimens to elicit potent CSP specific adaptive responses
was also analysed in animals that were made Ad5 im-
mune prior to receipt of the various vaccine regimens.
BALB/cJ mice received two injections 14 days apart of
1x1010 vp/mouse of an Ad5 vector that does not express
a transgene (Ad5-Null). It has been previously dem-
onstrated that two immunizations with 1x1010 vps of
rAd5-Null vector induced Ad5 neutralizing antibodies
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Figure 3 Memory responses triggered by vaccination with homologous and heterologous prime boost regimens utilizing Ad4-CSP and
Ad5-CSP in Ad naïve mice. Splenocytes (B-C) and PBMCs (D-E) were collected two weeks after final vaccination. Cells were stained for
CD62L-V450, CD127-PerCP Cy5.5, and CSP (NYD) tet-PE. CSP specific central memory T cells were determined as CD62L+ CD127+ cells that are tet
+ and effector memory cells are CD62Llo CD127+ cells that are tet+. Provided above is an example of gating (A). Bars represent ± standard error.
Statistical analysis was completed using One Way ANOVA with Student-Newman-Keuls post-hoc test, **, *** denotes significance over naïve,
P< 0.01, P< 0.001.
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populations [39]. 14 days after the last injection of Ad5-
Null, Ad5-immune animals received 1×1010 vp/mouse
prime injection of either Ad4-CSP or Ad5-CSP followed
by either a heterologous or homologous boost 14 days
after the initial priming vaccination. 28 days after the
prime vaccination plasma, PBMCs, and splenocytes werecollected. Splenocytes were stimulated as before with
NYDNAGTNL and were analyzed for CSP specific IFNγ
secreting cells by ELISpot. Ad5-CSP/Ad4-CSP, Ad4-
CSP/Ad4-CSP, and Ad4-CSP/A5-CSP vaccinated Ad5
immune animals all had significantly higher numbers of
NYDNAGTNL responsive IFNγ secreting cells present






























Figure 4 All vaccinations stimulated significantly higher
anti-CSP total IgG than unvaccinated and AD4-CSP/Ad4-CSP
vaccination in Ad naïve animals. Plasma was collected 14 days
post the final vaccination. Plasma was diluted 1:100, 1:200, and 1:400
and measured for total IgG against CSP by ELISA. Bars
represent ± standard error. Statistical analysis was completed using
One Way ANOVA with Student-Newman-Keuls post-hoc test, *, **,
*** denotes significance over naïve, P< 0.05, P<0.01, P< 0.001. ###
denotes significance over Ad4-CSP/Ad4CSP treatment, P< 0.001.
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pared to Ad5 naive animals, overall induction of NYD-
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Figure 5 Ad5-CSP/Ad5-CSP and Ad4-CSP/Ad5-CSP both stimulated
more percent specific killing than unvaccinated animals. 14 days
post vaccination splenocytes from naïve animals were pulsed with either
NYDNAGTNL and high concentration of CFSE or non-specific peptide
and low concentration of CFSE. Stained splenocytes were combined in
equal amounts and roughly 8 million cells were injected into vaccinated
animals IV. After 20 hours splenocytes from vaccinated mice were
collected and analysed by flow cytometry to assess the amount of
NYDNAGTNL specific killing. % Specific killing=1-((%CFSEhigh/%CFSElow)
immunized/(%CFSE
high/CFSElow)non-immunized. Bars represent± standard error.
Statistical analysis was completed using One Way ANOVA with
Student-Newman-Keuls post-hoc test, **denotes significance over naïve,
P<0.01.notably diminished in Ad5 immune animals despite use
of Ad4-CSP in some of the regimens (Table 1). The re-
ductions prevented detection of significant differences
between the treatments when ICS of the splenocytes for
IFNγ, TNF, and Granzyme B was undertaken (Additional
file 4A-C).
PBMCs and splenocytes were then analysed for CD3+
CD8+ T cells that were CSP peptide tetramer binding by
flow cytometry and found that all vaccinated Ad5 im-
mune animals, including Ad5-CSP/Ad5-CSP vaccinated
animals, had a significantly higher percentage of CSP
specific CD3+ CD8+ tet+ T cells present in both the
spleen and peripheral blood (Figure 7A-B). All treat-
ments including Ad5-CSP/Ad5-CSP also had signifi-
cantly higher percentages of tetramer positive Tcm cells
when compared to the non-vaccinated animals in both
the spleen and in the peripheral blood (Figure 8B, D).
Only mice from the Ad5-CSP/Ad5-CSP treatment group
had higher frequencies of CSP specific Tem cells in their
spleens as compared to non vaccinated mice (Figure 8C).
Ad5-CSP/Ad5-CSP, Ad5-CSP/Ad4-CSP, and Ad4-CSP/
Ad4-CSP vaccination groups all stimulated signifi-
cantly more Tem cells in the peripheral blood than
non-vaccinated and Ad4-CSP/Ad5-CSP vaccinated
Ad5 immune-animals (Figure 8E). T cells memory
phenotypes were measured and it was found that hom-
































Figure 6 IFNγ secretion of cells from Ad5 immune mice
vaccinated with heterologous and homologous prime boost
regimens utilizing Ad4-CSP and Ad5-CSP. All vaccinations were
capable of stimulating significantly more IFNγ secreting cells than
unvaccinated and Ad5-CSP/Ad5-CSP vaccinated Ad5 immune
animals. Splenocytes were collected 14 days after final vaccination.
Splenocytes were then stimulated with CSP dominant antigen
NYDNAGTNL and IFNγ secretion was measure by ELISpot. Bars
represent ± standard error. Statistical analysis was completed using
One Way ANOVA with Student-Newman-Keuls post-hoc test,
*, ** denotes significance over naïve, P< 0.05, P< 0.01.
Table 1 Decreased mean spot forming cells in Ad5
immune animals






All vaccinations, inclusive of homologous Ad4-CSP prime boost, elicited fewer
IFNγ secreting splenocytes in Ad5 immune animals as measured by ELISpot.
The table displays the mean numbers of spot forming cells per 500,000
splenocytes from spleens of Ad5 naïve and Ad5 immune mice treated with
each prime boost regimen.
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memory in Ad5 immune mice (Figure 9). The in vivo
cytolytic activity of CD8+ T cells in Ad5 pre-immune
mice was also evaluated. No significant increase in per-
cent specific killing was observed in any treatment
groups when compared to unvaccinated Ad5 immune
animals (data not shown). Undiluted plasma collected
from unvaccinated animals and Ad5 immune animals
from each vaccination regimen was analysed for anti-
CSP total IgG by ELISA. From the undiluted plasma, it
was found that Ad5-CSP/Ad4-CSP, Ad4-CSP/Ad4-CSP,
and Ad4-CSP/A5-CSP vaccinated animals all had signifi-
cantly more CSP specific total IgG than non-vaccinated
animals (p < 0.001) and the Ad5 immune animals homo-
logously vaccinated with Ad5-CSP (p < 0.001)
(Figure 10).
Conclusions
Ad4 has many qualities that make it a desirable choice
































Figure 7 All vaccinations in Ad5 immune animals resulted in significa
unvaccinated Ad5 immune animals. Splenocytes and PBMCs were collec
in significantly higher percentage of CD3+ CD8+ NYDNAGTNL tetramer pos
flow cytometry, cells were stained with CD8-Alexa flour700, CD3-APC-Cy7,
analysis was completed using One Way ANOVA with Student-Newman-Keurobust early innate responses and a high rate of infectiv-
ity [34]. Ad4 also has a long history of use as a vaccine
being used as an enteric live Ad4 vaccine by the military
to vaccinate recruits against ARD [29-32]. For these rea-
sons Ad4 has already been utilized as a potential HIV
vaccine vector in several large animal HIV models
[24,25]. This study investigated how Ad4 based vaccines
might be incorporated into malaria vaccine regimens,
either in isolation, or in combination with a first gener-
ation Ad5 vaccine platform.
The combination of a priming vaccination of Ad4-CSP
boosted by Ad5-CSP in Ad5 naïve animals results in in-
duction of higher levels of activated CD8+ T cells than
any other vaccination regimen used in this study. The
activated T cells induced by an Ad4-CSP priming vaccin-
ation boosted by Ad5-CSP are also capable of potent
CSP specific killing to levels that are equivalent to use of
Ad5-CSP homologous vaccinations, despite the fact that
animals homologously vaccinated with Ad5-CSP had
higher levels of CSP specific CD8+ T cells detectable by
staining with antibodies for CD3, CD8, and tetramer
specific for CSP. These data suggest that combined use
of Ad4-CSP priming followed by an Ad5-CSP boosting
vaccination induced more efficient cytotoxic T cell killers
than those induced by homologous prime boost of Ad5-
CSP. If the aim is to provide a large quantity of CSP
reactive T cells, a homologous prime boost vaccination
of Ad5-CSP should be utilized. However, if one wishes
to elicit IFNγ and TNF secreting T cells specific for CSP,
these results suggest that a priming vaccination with
Ad4-CSP followed by a boosting vaccination with Ad5-
CSP may be preferable.
While Ad4-CSP provided benefit when utilized as a
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and CSP (NYD)-Tetramer-PE. Bars represent ± standard error. Statistical


















































































































































































Figure 8 Memory responses triggered by vaccination with homologous and heterologous prime boost regimens utilizing Ad4-CSP and
Ad5-CSP in Ad5 immune animals. Splenocytes (B-C) and PBMCs (D-E) were collected two weeks after final vaccination. Cells were stained for
CD62L-V450, CD127-PerCP Cy5.5, and CSP (NYD) tet-PE. CSP specific central memory T cells were determined as CD62L+ CD127+ cells that are
tet+ and effector memory cells are CD62Llo CD127+ cells that are tet+. Provided above is an example of gating (A). Bars represent ± standard error.
Statistical analysis was completed using One Way ANOVA with Student-Newman-Keuls post-hoc test, *, **, *** denotes significance over naïve,
P< 0.05, P < 0.01, P< 0.001.
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stimulate potent CSP specific immune responses in
homologous prime boost regimens. Additionally, boost-
ing a prime of Ad5-CSP with Ad4-CSP induced very
poor CSP specific immune responses in general.Diminished induction by Ad4 based vaccines of
transgene-specific IgG has been previously observed,
and the effect was suggested to be a result of the Ad4
capsid inducing high levels of IFN-β, interfering with the









Ad5CSP/Ad5CSP Ad5CSP/Ad4CSP Ad4CSP/Ad4CSP Ad4CSP/Ad5CSPA











































































Figure 9 Memory Phenotype. Homologous prime boost regimens favor a Tcm cell phenotype in the peripheral blood of Ad5 immmune mice.
Memory phenotype was defined as percent of CSP (NYD) tetramer positive cells that are Tem cells (CD62L
lo CD127+) and percentage that are
Tcm cells (CD62L
+ CD127+) as opposed to percent of Tem and Tcm cells that are Tet
+. PBMCs were collected on day 14 post final injection and
stained according to the above defined memory phenpotype. Example of gating appears above the graphs (A). Percentage of Tcm Cells was
significantly higher PBMCs from homologously boosted animals in Ad5 immune mice (B). There was no significant difference in the percentage
of Tem cells present between any of the groups (C). Bars represent ± standard error. Statistical analysis was completed using One Way ANOVA
with Student-Newman-Keuls post-hoc Test.
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moter may ultimately reduce the length of time the CSP
antigen is expressed from Ad4 vaccine platforms, and
may explain the decrease in efficacy when Ad4-CSP is
utilized in isolation or as a boosting vaccination in
current studies [34].
To obtain protection from liver stage malaria, the
presence of Tem cells are thought to be an essential
element and a significant correlate to predicting vaccine
efficacy [38]. Among the vaccination regimens, the in-
duction of CSP specific Tem cell and Tcm cells were
grossly similar when Ad4 or Ad5 based CSP vaccine
treatments were conducted in Ad naïve animals. How-
ever, vaccination regimens did not perform equally when
in vivo cytotoxicity was tested, as only the animals re-
ceiving an Ad4-CSP priming vaccination boosted by
Ad5-CSP, and the animals receiving the homologous
Ad5-CSP prime-boost vaccination regimens resulted indetection of significantly improved levels of CSP specific
cell killing, as compared to non-vaccinated animals.
Since 14 days post vaccination is within the time frame
when peak CD8+ effector T cell responses may be
present, and CD8+ T cell contraction usually does not
take place until after three weeks post-vaccination, it is
likely that the observed CSP specific killing is a result of
the lingering presence of CD8+ effector T cells, rather
than induction of Tem cells.
Another reason to undertake these studies was to de-
termine if the use of serologically distinct Ad4 based
malaria targeted vaccines might allow for improved in-
duction of CSP immune responses, relative to repeated
use of Ad5, in Ad5 immune animals. Indeed, Ad4-CSP
was capable of stimulating the induction of significantly
more CSP antigen specific IFNγ secreting splenocytes,
as well as higher levels of anti-CSP antibodies when
















Ad5CSP Ad4CSP Ad4CSP Ad5CSP
Figure 10 All vaccinations stimulated significantly higher
anti-CSP total IgG than unvaccinated and Ad5-CSP/Ad5-CSP
vaccination in Ad5 immune animals. Plasma was collected
14 days post the final vaccination. Plasma was measured undiluted
for total IgG against CSP by ELISA. Serial dilutions were not possible
as the undiluted plasma data point required the majority of the
plasma collected from an animal. Bars represent ± standard error.
Statistical analysis was completed using One Way ANOVA with
Student-Newman-Keuls post-hoc test, *** denotes significance over
naïve, P< 0.001.
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However, these levels were below what was observed
when the Ad4-CSP vaccine was utilized in Ad5 naïve
animals. Furthermore, functional analysis suggested that
use of Ad4 in Ad5 immune animals also did not result
in improved induction of CSP specific cytotoxic activity
as compared to non-vaccinated animals. Although Ads
are segregated into subgroups based primarily on anti-
sera neutralization there is evidence that T cell responses
can react across Ad subgroups in humans [40]. These
cross reactive T cells could be responsible for the de-
creased immunogenicity observed in Ad5 immune ani-
mals homologously vaccinated with Ad4-CSP. Therefore,
a priori assumptions regarding lack of likely cross
neutralization by utilizing different subgroups of adeno-
virus must be reconsidered in light of these types of
functional, in vivo data. Likely, mild cross reactivity not
measured by conventional means (such as the neutraliz-
ing antibody and ELISpot based assays used in this
study) is still capable of diminishing immunogenicity of
two very distinct serotypes on the basis of perhaps only
a few cross reactive epitopes [41].
Prior immunity to Ad5 did not appear to affect the
ability of any of the Ad4-CSP or Ad5-CSP vaccination
regimens to induce CSP specific CD8+ T cells. The per-
centages of CSP specific tetramer positive CD8+ T cells
observed in Ad5 immune animals were similar to per-
centages observed in Ad naive animals. All vaccinations
appeared to increase the percentage of CD8+ T cellsspecific to the CSP epitope NYDNAGTNL in Ad5 im-
mune animals in spite of the observed ablation in cyto-
kine production by these same cells. Similarly, all
vaccinations except an Ad4-CSP prime boosted by Ad5-
CSP resulted in high percentages of CSP specific Tem
cells in the circulating blood. Heterologous prime boost
vaccinations even appear to trend toward a Tem cell
phenotype while homologous vaccinations biased toward
a Tcm cell phenotype. However, none of these responses
correlated with evidence of improved in vivo CSP spe-
cific cytotoxic T cell killing when either of these vectors
were deployed into Ad5 immune animals. Ad5 cross
reactivity with Ad4 appears to result in the ablation of
IFNγ and TNF secreting CSP specific cytotoxic T cells
induction by Ad4-CSP based vaccines, despite allowing
for the induction of high percentages of CSP specific T
cells.
The data shows that there exists a complex interaction
between immune responses triggered by a rAd4
(subgroup E) and those triggered by rAd5 (subgroup C),
each expressing the same malaria antigen, in this in-
stance, CSP. While combined use of Ad4-CSP priming
vaccinations with Ad5-CSP boosting vaccinations results
in the induction of greater numbers of CSP responsive
cytokine secreting, cytotoxic T cells in Ad5 naïve ani-
mals, there appears to be interference between the two
seemingly distinct Ad subgroups, resulting in diminished
inductions of transgene specific immune responses in
Ad5 immune animals despite the use of the Ad4 plat-
form. Future studies need to be performed to further
elucidate the mechanism behind Ad4’s decreased ability
to stimulate immune responses in an Ad5 immune back-
ground. Based on these results it is important that future
use of alternative Ad serotypes be scrutinized under sim-
ilarly stringent assay conditions to ascertain their true
effectiveness in overcoming pre-existing Ad5 immunity.Additional files
Additional file 1: Ad4-CSP/Ad4-CSP and Ad5-CSP/Ad5-CSP
vaccinated animals have no significant cross stimulation of
splenocytes. Splenocytes were collected 14 days post final vaccination
and were stimulated with either heat inactivated Ad4-Null or heat
inactivated Ad5-Null. Animals treated with Ad5-CSP/Ad5-CSP were not
significantly different from naïve animals when stimulated with heat
inactivated Ad4-CSP as measured by IFNγ secretion by ELISpot. Likewise,
animals treated with Ad4-CSP/Ad4-CSP were not significantly different
from naïve animals when stimulated with heat inactivated Ad5-CSP as
measured by IFNγ secretion by ELISpot. Bars represent ± standard error.
Statistical analysis was completed using One Way ANOVA with Student-
Newman-Keuls post-hoc test, *, **, *** denotes significance over naïve,
P< 0.05, P< 0.01, P< 0.001.
Additional file 2: Sub-isotype analysis of IgG antibody from plasma
of mice vaccinated with heterologous and homologous prime boost
regimens utilizing Ad4-CSP and Ad5-CSP. Plasma was collected
14 days post final vaccination. The amount of CSP specific subisotype
IgG1 (A), IgG2a (B), IgG2b (C), and IgG3 (D) were analysed by ELISA. Bars
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http://www.malariajournal.com/content/11/1/209represent ± standard error. Statistical analysis was completed using One
Way ANOVA with Student-Newman-Keuls post-hoc test, *, **, *** denotes
significance over naïve, P< 0.05, P< 0.01, P< 0.001.
Additional file 3: Th1 to Th2 ratio (IgG2a/IgG1) of plasma from
vaccinated Ad naïve animals. Plasma was collected 14 days post final
vaccination. The amount of CSP specific IgG subisotypes was measured
by ELISA. Th1 to Th2 ratio was determined by dividing O.D. values from
IgG2a and IgG1. Bars represent ± standard error. Statistical analysis was
completed using One Way ANOVA with Student-Newman-Keuls post-hoc
test, * denotes significance over naïve, P< 0.05.
Additional file 4: CD8+ T cell activation in Ad5 immune animals
vaccinated with heterologous or homologous prime boost
regimens utilizing Ad4-CSP and Ad5-CSP. Splenocytes were collected
from vaccinated animals 14 days post the final vaccination. Cells were
stained with CD8-Alexa flour700, CD3-APC-Cy7, TNFα-PE-Cy7, IFNγ-FITC,
and Granzyme B-APC and analysed by flow cytometry for INFγ secreting
CD3+ CD8+ T cells (A), TNFα secreting CD3+ CD8+ T cells (B), and
granzyme B+ CD3+ CD8+ T cells (C). Bars represent ± standard error.
Statistical analysis was completed using One Way ANOVA with
Student-Newman-Keuls post-hoc test, *, **, *** denotes significance over
naïve, P< 0.05, P< 0.01, P< 0.001.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NS Carried out animal injections, performed all ELISA, ELISpot and in vivo CTL
assays, assisted with Ad5-CSP design and development, and drafted the
manuscript. YA performed all other flow cytometry experiments. SG
designed and developed Ad4-CSP and assisted with animal work. SS assisted
with design and development of Ad4-CSP. YK designed and developed Ad5-
CSP. AA conceived of the study and participated in design and coordination.
All authors read and approved the final manuscript.
Acknowledgments
We wish to thank Michigan State University Laboratory Animal support
facilities for their assistance in the humane care and maintenance of the
animals utilized in this work, the NIH Core Tetramer Facility at Emory
University for manufacturing the NYDNAGTNL tetramer, and the Michigan
State University flow cytometry facility for their assistance with the multiple
experiments. AA was supported by the Osteopathic Heritage Foundation, as
well the MSU Foundation.
Author details
1Genetics Program, Michigan State University, 2240 E Biomedical and
Physical Sciences Building, East Lansing, MI 48824, USA. 2Department of
Pediatrics, Michigan State University, East Fee Hall, East Lansing, MI 48824,
USA. 3Department of Microbiology and Molecular Genetics, Michigan State
University, 2215, USA Biomedical and Physical Sciences Building, East
Lansing, MI 48824, USA. 4College of Osteopathic Medicine, Michigan State
University, East Fee Hall, East Lansing, MI 48824, USA.
Received: 12 March 2012 Accepted: 16 May 2012
Published: 21 June 2012
References
1. WHO: World Malaria Report 2009. Geneva: World Health Organization; 2008.
2. Good MF, Pombo D, Quakyi IA, Riley EM, Houghten RA, Menon A, Alling DW,
Berzofsky JA, Miller LH: Human T-cell recognition of the circumsporozoite
protein of Plasmodium falciparum: immunodominant T-cell domains map to
the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988,
85:1199–1203.
3. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R,
Heppner DG, Yuan G, Hollingdale M, Slaoui M: Safety, immunogenicity,
and efficacy of a recombinantly produced Plasmodium falciparum
circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
J Infect Dis 1995, 171:1576–1585.
4. Zhou Z, Xiao L, Branch OH, Kariuki S, Nahlen BL, Lal AA: Antibody
responses to repetitive epitopes of the circumsporozoite protein, liver
stage antigen-1, and merozoite surface protein-2 in infants residing in aPlasmodium falciparum-hyperendemic area of western Kenya. XIII.
Asembo Bay Cohort Project. AmJTrop Med Hyg 2002, 66:7–12.
5. Arun Kumar K, Sano G-i, Boscardin S, Nussenzweig RS, Nussenzweig MC,
Zavala F, Nussenzweig V: The circumsporozoite protein is an
immunodominant protective antigen in irradiated sporozoites. Nature
2006, 444:937–940.
6. Vogels R, Zuijdgeest D, van Meerendonk M, Companjen A, Gillissen G,
Sijtsma J, Melis I, Holterman L, Radosevic K, Goudsmit J, Havenga MJ:
High-level expression from two independent expression cassettes in
replication-incompetent adenovirus type 35 vector. J Gen Virol 2007,
88:2915–2924.
7. Plassmeyer ML, Reiter K, Shimp RL Jr, Kotova S, Smith PD, Hurt DE, House B,
Zou X, Zhang Y, Hickman M, Uchime O, Herrera R, Nguyen V, Glen J,
Lebowitz J, Jin AJ, Miller LH, MacDonald NJ, Wu Y, Narum DL: Structure of
the Plasmodium falciparum circumsporozoite protein, a leading malaria
vaccine candidate. J Biol Chem 2009, 284:26951–26963.
8. Coppi A, Natarajan R, Pradel G, Bennett BL, James ER, Roggero MA,
Corradin G, Persson C, Tewari R, Sinnis P: The malaria circumsporozoite
protein has two functional domains, each with distinct roles as
sporozoites journey from mosquito to mammalian host. J Exp Med 2011,
208:341–356.
9. Kappe SH, Buscaglia CA, Nussenzweig V: Plasmodium sporozoite
molecular cell biology. Annu Rev Cell Dev Biol 2004, 20:29–59.
10. The RTS SCTP: First results of Phase 3 trial of RTS, S/AS01 malaria vaccine
in African children. NEJM 2011, 365:1863–1875.
11. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE,
Heppner DG, Krzych U: Protective immunity induced with malaria
vaccine, RTS, S, is linked to Plasmodium falciparum circumsporozoite
protein-specific CD4+ and CD8+ T cells producing IFN-{gamma}.
J Immunol 2003, 171:6961–6967.
12. Kester Kent E, Cummings James F, Ofori-Anyinam O,
Ockenhouse Christian F, Krzych U, Moris P, Schwenk R, Nielsen Robin A,
Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA,
Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG Jr, RTS,S
Vaccine Evaluation Group: Randomized, double-blind, Phase 2a trial of
falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-
naive adults: safety, efficacy, and immunologic associates of protection.
J Infect Dis 2009, 200:337–346.
13. Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM,
Schwenk RJ, Krzych U, Holland CA, Richmond G, Dowler MG, Williams J,
Wirtz RA, Tornieporth N, Vigneron L, Delchambre M, Demoitie MA,
Ballou WR, Cohen J, Heppner DG Jr, RTS, S Malaria Vaccine Evaluation
Group: Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day
immunization schedules of malaria vaccine RTS, S/AS02 in malaria-naïve
adults at the Walter Reed Army Institute of Research. Vaccine 2008,
26(18):2191–2202.
14. Casares S, Brumeanu TD, Richie TL: The RTS, S malaria vaccine. Vaccine
2010, 28(31):4880–4894.
15. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S,
Lang T, Gould J, Dubois M-C, Demoitié MA, Stallaert JF, Vansadia P, Carter T,
Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N,
Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM,
Lemnge MM, Marsh K, von Seidlein L: Efficacy of RTS, S/AS01E vaccine
against malaria in children 5 to 17 months of age. NEJM 2008,
359:2521–2532.
16. Appledorn DM, McBride A, Seregin S, Scott JM, Schuldt N, Kiang A,
Godbehere S, Amalfitano A: Complex interactions with several arms of
the complement system dictate innate and humoral immunity to
adenoviral vectors. Gene Ther 2008, 15:1606–1617.
17. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AVS: Viral vectors
as vaccine platforms: deployment in sight. Curr Opin Immunol 2011,
23:377–382.
18. Houghton M: Prospects for prophylactic and therapeutic vaccines against
the hepatitis C viruses. Immunol Rev 2011, 239:99–108.
19. Ophorst OJ, Radosevic K, Havenga MJ, Pau MG, Holterman L, Berkhout B,
Goudsmit J, Tsuji M: Immunogenicity and protection of a recombinant
human adenovirus serotype 35-based malaria vaccine against
Plasmodium yoelii in mice. Infect Immun 2006, 74:313–320.
20. Shott JP, McGrath SM, Pau MG, Custers JHV, Ophorst O, Demoitié M-A,
Dubois M-C, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J,
Heppner DG, Stewart VA: Adenovirus 5 and 35 vectors expressing
Schuldt et al. Malaria Journal 2012, 11:209 Page 14 of 14
http://www.malariajournal.com/content/11/1/209Plasmodium falciparum circumsporozoite surface protein elicit potent
antigen-specific cellular IFN-[gamma] and antibody responses in mice.
Vaccine 2008, 26:2818–2823.
21. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin S-W, Li Y,
Giles-Davis W, Cun A, Zhou D, Xiang Z, Letvin NL, Ertl HC: Effect of
preexisting immunity to adenovirus human serotype 5 antigens on the
immune responses of nonhuman primates to vaccine regimens based
on human- or chimpanzee-derived adenovirus vectors. J Virol 2007,
81:6594–6604.
22. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S,
Holterman L, Damen I, Vogels R, Thorner AR, O’Brien KL, Carville A,
Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH: Comparative
seroprevalence and immunogenicity of six rare serotype recombinant
adenovirus vaccine vectors from subgroups B and D. J Virol 2007,
81:4654–4663.
23. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S,
Ng’ang’a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S,
Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul
PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR,
Carville A, Mansfield KG, Pau MG, Goudsmit J: International
seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric
and adult populations. Vaccine, . In Press, Corrected Proof.
24. Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS,
Bhat BM, Mizutani S, Lee S: Adenovirus-human immunodeficiency virus
(HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing
antibodies in the dog model. Proc Natl Acad Sci USA 1992, 89:7777–7781.
25. Lubeck MD, Natuk RJ, Chengalvala M, Chanda PK, Murthy KK, Murthy S,
Mizutani S, Lee SG, Wade MS, Bhat BM: Immunogenicity of recombinant
adenovirus-human immunodeficiency virus vaccines in chimpanzees
folowing intranasal administration. AIDS Res Hum Retroviruses 1994,
10:1443–1449.
26. Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M,
Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers
JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr: Priming with an
adenovirus 35-circumsporozoite protein (cs) vaccine followed by RTS,
S/AS01B boosting significantly improves immunogenicity to Plasmodium
falciparum CS compared to that with either malaria vaccine alone. Infect
Immun 2007, 75:2283–2290.
27. Rodríguez A, Mintardjo R, Tax D, Gillissen G, Custers J, Pau MG, Klap J,
Santra S, Balachandran H, Letvin NL, Goudsmit J, Radosević K: Evaluation of
a prime-boost vaccine schedule with distinct adenovirus vectors against
malaria in rhesus monkeys. Vaccine 2009, 27:6226–6233.
28. Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks
MDJ, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV:
Enhancing blood-stage malaria subunit vaccine immunogenicity in
rhesus macaques by combining adenovirus, poxvirus, and
protein-in-adjuvant vaccines. J Immunol 2010, 185:7583–7595.
29. Hilleman MR: Epidemiology of adenovirus respiratory infections in
military recruit populations. Ann NY Acad Sci 1957, 67:262–272.
30. Top FH Jr, Dudding BA, Russell PK, Buescher EL: Control of respiratory
disease in recruits with type 4 and 7 adenovirus vaccines. Am J Epidemiol
1971, 94:142–146.
31. Jr FHT, Grossman RA, Bartelloni PJ, Segal HE, Burton AD, Russell PK,
Buescher EL: Immunization with live types 7 and 4 adenovirus vaccines. I.
Safety, infectivity, antigenicity, and potency of adenovirus type 7
vaccine in humans. J Infect Dis 1971, 124:148–154.
32. Jr FHT, Buescher EL, Bancroft WH, Russell PK: Immunization with live types
7 and 4 adenovirus vaccines. II. Antibody response and protective effect
against acute respiratory disease due to adenovirus type 7. J Infect Dis
1971, 124(2):155–160.
33. Schuldt NJ, Aldhamen YA, Appledorn DM, Seregin SS, Kousa Y,
Godbehere S, Amalfitano A: Vaccine platforms combining
circumsporozoite protein and potent immune modulators, rEA
or EAT-2, paradoxically result in opposing immune responses. PLoS One
2011, 6:e24147.
34. Hartman ZC, Appledorn DM, Serra D, Glass O, Mendelson TB, Clay TM,
Amalfitano A: replication-attenuated human adenoviral type 4 vectors
elicit capsid dependent enhanced innate immune responses that are
partially dependent upon interactions with the complement system.
Virology 2008, 374:453–467.35. Appledorn DM, Aldhamen YA, DePas W, Seregin SS, Liu C-JJ, Schuldt N,
Quach D, Quiroga D, Godbehere S, Zlatkin I, Kim S, McCormick JJ,
Amalfitano A: A new adenovirus based vaccine vector expressing an
Eimeria tenella rerived TLR agonist improves cellular immune responses
to an antigenic target. PLoS One 2010, 5:e9579.
36. Blum-Tirouvanziam U, Beghdadi-Rais C, Roggero M, Valmori D, Bertholet S,
Bron C, Fasel N, Corradin G: Elicitation of specific cytotoxic T cells by
immunization with malaria soluble synthetic polypeptides. J Immunol
1994, 153:4134–4141.
37. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D,
Koup RA, Roederer M: Amine reactive dyes: an effective tool to
discriminate live and dead cells in polychromatic flow cytometry. J
Immunol Meth 2006, 313:199–208.
38. Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill
AVS: CD8+ T effector memory cells protect against liver-stage malaria.
J Immunol 2011, 187:1347–1357.
39. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Amalfitano A, Jones FR: Novel
adenovirus type 5 vaccine platform induces cellular immunity against
HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009,
27:6394–6398.
40. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HCJ, Betts MR:
Adenovirus-specific human T cells are pervasive, polyfunctional, and
cross-reactive. Vaccine 2010, 28:1932–1941.
41. Thorner AR, Lemckert AAC, Goudsmit J, Lynch DM, Ewald BA, Denholtz M,
Havenga MJE, Barouch DH: Immunogenicity of heterologous recombinant
adenovirus prime-boost vaccine regimens is enhanced by circumventing
vector cross-reactivity. J Virol 2006, 80:12009–12016.
doi:10.1186/1475-2875-11-209
Cite this article as: Schuldt et al.: Immunogenicity when utilizing
adenovirus serotype 4 and 5 vaccines expressing circumsporozoite
protein in naïve and Adenovirus (Ad5) immune mice. Malaria
Journal 2012 11:209.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
